Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    Subscribe
    • Home
    • Top Stories
    • Business
    • Tech
    • Companies
    • Events
    • Announcements
    Home»BioTech»APOLLOMICS INC. ANNOUNCES OFFICIAL OPENING OF SHANGHAI BRANCH
    BioTech

    APOLLOMICS INC. ANNOUNCES OFFICIAL OPENING OF SHANGHAI BRANCH

    Marie JonesBy Marie JonesMay 20, 2021No Comments2 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that Apollomics Shanghai Branch has been officially opened and started its operations at Zhangjiang Hi-Tech Park, Pudong District, Shanghai.

    Dr. Guoliang Yu, the company’s Co-Founder, Chairman and CEO said, “In 2018, we established a Chinese company in Hangzhou, and our Chinese team has grown from a few people to dozens of people. The Shanghai branch is located in the Silicon Valley of bioinnovative drugs in China, Zhangjiang Medicine Valley, which has gathered top talent from research and development, clinical and commercialization. Many of our clinical trials in China are soon to be carried out. The establishment of the Shanghai branch will be more conducive to the construction of our diverse talent team and will also promote connection and communication with domestic and foreign partners.”

    About Apollomics, Inc.
    Apollomics, Inc. is an innovative biopharmaceutical company committed to the discovery and development of monotherapies and combination therapies of tumor-targeting agents and immuno-oncology agents. It has operating entities in Foster City, California, USA and Hangzhou, China. The company’s product pipeline has many projects at different stages of development, including novel, humanized monoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. For more information, please visit www.apollomicsinc.com.

    Contact information of Apollomics:
    Investor Contact:
    Wilson W. Cheung
    Chief Financial Officer
    Telephone: +1-650-209-4436
    Email: wcheung@apollomicsinc.com

    Company Contact:
    Liping Zhang
    Telephone: +86-571-83521933
    Email: liping.zhang@apollomicsinc.com

    U.S. Media Contact:
    Remy Bernarda
    Corporate Communications
    (415) 203-6386
    remy.bernarda@apollomicsinc.com

    China Media Contact:
    Porda Havas International Finance Communications Group

    Kelly Fung
    General Manager
    Telephone: (852) 3150 6763
    Email: kelly.fung@pordahavas.com

    Phoenix Fung
    Assistant Vice President
    Telephone: (852) 3150 6773
    Email: phoenix.fung@pordahavas.com

    Apollomics Inc
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleUSFDA recognized Antrodia cinnamomea mycelia (NDIN No.1170)
    Next Article Sweet Expands NFT Marketplace to Shopify Ecosystem

    Related Posts

    AcroMeta to Enter Ambient Temperature Cellular Logistics Through Strategic Partnership with Macro HRD SG Pte. Ltd.

    September 7, 2026

    Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 Billion

    September 7, 2026

    CMS (867.HK/8A8.SG): Innovative Drug Lumirix(R) Approved in China for Additional Indication of Atopic Dermatitis (AD)

    September 4, 2026
    Add A Comment

    Comments are closed.

    © 2026 BusinessNewsAsia.com
    • About Us
    • Contact Us
    • BusinessNews.ph
    • AsiaPEVC.com
    • DevFiNews.com
    • RenewableEnergy.ph

    Type above and press Enter to search. Press Esc to cancel.